This company has been marked as potentially delisted and may not be actively trading. NASDAQ:ODT Odonate Therapeutics (ODT) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisBuy This Stock About Odonate Therapeutics Stock (NASDAQ:ODT) 30 days 90 days 365 days Advanced Chart Get Odonate Therapeutics alerts:Sign Up Key Stats Today's Range N/A50-Day Range$1.03▼$1.5552-Week Range N/AVolume87,682 shsAverage VolumeN/AMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewOdonate Therapeutics is a pharmaceutical company dedicated to the development of best-in-class therapeutics that improve and extend the lives of patients with cancer. Our initial focus is on the development of tesetaxel, a novel chemotherapy agent that belongs to a class of drugs known as taxanes, which are widely used in the treatment of cancer. Tesetaxel has several potential therapeutic advantages over currently available taxanes, including: oral administration with a low pill burden and a patient-friendly dosing regimen; a formulation that does not contain solubilizing agents that are known to cause hypersensitivity (allergic) reactions; and improved activity against chemotherapy-resistant tumors. Tesetaxel has been generally well tolerated in clinical studies and has demonstrated robust single-agent antitumor activity in two Phase 2 studies in patients with locally advanced or metastatic breast cancer (''MBC'').Read More… Receive ODT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Odonate Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address ODT Stock News HeadlinesOdonate Inc ODTCJuly 28, 2024 | morningstar.comMProQR Therapeutics NV (PRQR)February 6, 2024 | investing.comWhen This Happens, You Don’t Wait. You Act.This same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in crypto. Now it’s back, and the smart money is already positioning. A free training reveals the step-by-step strategy and altcoin picks designed to help you capitalize on the next wave. | Crypto Swap Profits (Ad)Orally Disintegrating Tablet (ODT) Market 2023 | Future Exploration by 2030March 29, 2023 | marketwatch.comPfizer recalls migraine drug Nurtec ODT after millions of products lacked child resistant packagingMarch 19, 2023 | usatoday.comFate Therapeutics Stock (NASDAQ:FATE), Analyst Ratings, Price Targets, PredictionsMarch 3, 2023 | benzinga.comOrally Disintegrating Tablet (ODT) Market Size 2023 with Big Company Segment, Cost-Effective Solutions Analysis Information 2029January 30, 2023 | marketwatch.comODTC Odonate Therapeutics, Inc.October 22, 2022 | seekingalpha.comSee More Headlines ODT Stock Analysis - Frequently Asked Questions How were Odonate Therapeutics' earnings last quarter? Odonate Therapeutics, Inc. (NASDAQ:ODT) released its quarterly earnings data on Wednesday, November, 10th. The company reported ($0.37) earnings per share for the quarter, missing analysts' consensus estimates of ($0.04) by $0.33. When did Odonate Therapeutics IPO? Odonate Therapeutics (ODT) raised $150 million in an initial public offering on Thursday, December 7th 2017. The company issued 5,900,000 shares at a price of $24.00-$27.00 per share. Goldman Sachs and Jefferies served as the underwriters for the IPO and Cowen was co-manager. What other stocks do shareholders of Odonate Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Odonate Therapeutics investors own include Intel (INTC), Sorrento Therapeutics (SRNE), AbbVie (ABBV), Energy Transfer (ET), Pfizer (PFE), Exxon Mobil (XOM) and Advanced Micro Devices (AMD). Company Calendar Last Earnings11/10/2021Today6/28/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:ODT CIK1717452 Webwww.odonate.com Phone(858) 731-8180FaxN/AEmployees145Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding Shares28,530,000Free Float14,578,000Market CapN/A OptionableNot Optionable BetaN/A Investing Strategies To Help Grow Your Retirement IncomeNeed to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.Get This Free Report This page (NASDAQ:ODT) was last updated on 6/28/2025 by MarketBeat.com Staff From Our PartnersGold Just Jumped Again. Here’s How to Get PaidGold prices just spiked again. As I write this, gold is trading near $3,400 an ounce. But here's the thi...Investors Alley | Sponsored"I'm risking my reputation on this"Behind closed doors, away from the mainstream media's eyes, the smartest minds in crypto are all seeing the sa...Crypto 101 Media | SponsoredCrypto Is Pumping Again – Now Comes the Real OpportunityThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredThe Shocking Link Between A.I. and Your MoneyThe AI boom isn’t just transforming technology—it’s redefining global power, increasing government debt, and u...Lear Capital | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredTrump Knows Exactly What He’s Doing…With Trump in office, new money is flowing in and out of the market like never before... And some folks usi...Brownstone Research | SponsoredThe mainstream media is wrong about AI — againThe mainstream media got it wrong … yet again. AI has recently turned the tech world on its head. And th...Weiss Ratings | SponsoredTrump set to Boost Social Security Checks by 400%?If you're currently collecting—or planning to collect—Social Security benefits, there's an urgent development ...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Odonate Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Odonate Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.